A recent study published in The New England Journal of Medicine has yielded groundbreaking results after a monoclonal antibody successfully eradicated rectal cancer in all enrolled patients, ushering them into complete remission without resorting to chemotherapy, radiation, or surgical interventions.
Dr. Andrea Cercek, one of the lead researchers, said, “It’s absolutely incredible. We didn’t expect it. We’ve certainly never seen this before. It’s really what, you know, cancer doctors’ dreams are made of to see a response like this. Such incredible efficacy with really, almost no toxicity.”
Twelve patients participated, with a median age of 54 and 62% being women. These individuals had advanced rectal cancer, which typically requires harsh treatments.
Patients were administered dostarlimab, a specific type of monoclonal antibody, every three weeks for six months, avoiding the conventional, often debilitating treatments associated with their condition.
Every participant experienced complete clinical remission, with no trace of tumors detected through magnetic resonance imaging (MRI).
The authors wrote:
“A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.”
How does this monoclonal antibody actually work? Dr. Cercek explained that it essentially unlocks the body’s ability to heal itself.
For more details, click here to read the study, or go here to watch the full video from The Epoch Times.
100% Cancer Remission Achieved in ALL Patients in Groundbreaking Study